RED 103004
Latest Information Update: 17 Dec 2003
At a glance
- Originator XiMed Group
- Developer Eden Research
- Class Obesity therapies
- Mechanism of Action Lipase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 17 Dec 2003 No development reported - Preclinical for Obesity in United Kingdom (unspecified route)
- 01 Jan 2002 Development discontinued for Obesity before 2002
- 01 May 2000 New profile